Sarepta Therapeutics Q1 Loss Widens - Quick Facts

(RTTNews) - Sarepta Therapeutics, Inc.(SRPT) reported a first-quarter net loss of $61.6 million or $1.49 per share, compared to a loss of $28.3 million or $0.75 per share, prior year. The company said the increase in net loss was primarily due to a decrease of $6.1 million from government contract revenue and increases of $18.3 million from research and development expenses and $12.4 million from general and administrative expenses. For the first quarter of 2015, Sarepta reported a non-GAAP net loss of $47.4 million, or $1.15 per share.

On average, 16 analysts polled by Thomson Reuters expected the company to report a loss per share of $1.01 for the quarter. Analysts' estimates typically exclude special items.

The company said its revenue for the first quarter of 2015 decreased by $6.1 million primarily due to the July 2014 expiration of the Marburg portion of its Ebola-Marburg U.S. government contract.